Related Experiment Video
Updated: Jun 20, 2026
08:17
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
15.5K
Thymic tumors: radiotherapy experience for single institute
Sureyya Sarihan1, Aybuke Tugce Metin2, Ahmet Sami Bayram3
1Faculty of Medicine, Department of Radiation Oncology, Bursa Uludag University, 16059, Bursa, Turkey. ssarihan@uludag.edu.tr.
Summary
Recurrence of thymic epithelial tumors (TET) can occur late. This study achieved 82.4% 5-year local control, identifying key prognostic factors for better personalized treatment.
Area of Science:
- Oncology
- Radiotherapy
- Thoracic Surgery
Background:
- Thymic epithelial tumors (TET) are rare neoplasms.
- Radiotherapy (RT) is a key treatment modality for TET.
- Understanding treatment outcomes and prognostic factors is crucial for optimizing patient care.
Purpose of the Study:
- To evaluate treatment outcomes in patients with thymic epithelial tumors (TET) treated with radiotherapy (RT).
- To identify prognostic factors influencing survival and recurrence in TET patients.
- To inform personalized treatment strategies for TET.
Main Methods:
- Retrospective analysis of 64 TET patients treated between 2000 and 2023.
- Patients received radiotherapy (RT) with a median dose of 5040 cGy.
- Staging utilized Masaoka-Koga and TNM classifications; WHO histology and Karnofsky Performance Status (KPS) were assessed.
Main Results:
- Median follow-up was 70 months; 23% experienced recurrence with a median time to recurrence of 30 months.
- Five-year local control was 82.4%, with mean overall survival (OS) and progression-free survival (PFS) of 141 and 138 months, respectively.
- Univariate analysis identified organ invasion and TNM stage as significant prognostic factors. Multivariate analysis revealed high-risk histology (B2/B3/C), surgical center, KPS ≤ 80, thymic carcinoma, and Masaoka-Koga stage III-IV as unfavorable prognostic factors for OS and PFS.
Conclusions:
- Thymic epithelial tumor (TET) recurrence can manifest over extended periods.
- Achieved 5-year local control of 82.4% highlights the efficacy of RT in TET management.
- Karnofsky Performance Status (KPS), histology, Masaoka-Koga stage, risk group, and surgical center are significant prognostic indicators, supporting personalized treatment approaches.
